Clinical trial
A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).
NCT03531060 is registered in ClinicalTrials.gov with Integrative Research Laboratories AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).
- Lead sponsor
- Integrative Research Laboratories AB
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 8, 2016
- Completion date
- April 12, 2017
- Enrollment
- 15 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.